Provide a valuable resource to your clients or customers by linking to this resource page. Just place the following link on your website.
Myfembree is a prescription combination medicine containing relugolix 40 mg, estradiol 1 mg, and norethindrone acetate 0.5 mg per tablet. It is indicated for management of heavy menstrual bleeding associated with uterine fibroids and moderate to severe pain associated with endometriosis in premenopausal women. Treatment is limited to 24 months because continued bone loss can be irreversible.
read more about myfembree ...Relugolix blocks gonadotropin-releasing hormone receptors in the pituitary gland, reducing ovarian estrogen and progesterone production. This decreases hormonal stimulation associated with fibroid-related bleeding and endometriosis pain. Estradiol replaces some of the suppressed estrogen to reduce certain low-estrogen effects, while norethindrone acetate helps protect the uterine lining from estrogen-related changes.
Myfembree is prescribed to premenopausal women with heavy menstrual bleeding caused by uterine fibroids or moderate to severe endometriosis-associated pain. Pregnancy is excluded before treatment, and hormonal contraceptives are discontinued. Patients with known osteoporosis, significant blood clot risk, certain hormone-sensitive cancers, or liver disease must not receive Myfembree. Safety and efficacy have not been established in pediatric patients.
Myfembree is taken as one tablet by mouth once daily at approximately the same time, with or without food. Treatment starts as early as possible after menstruation begins and no later than seven days after its onset. Total treatment duration must not exceed 24 months. Effective nonhormonal contraception is used during treatment and for one week after the final dose. Bone mineral density is assessed before and during treatment according to the indication.
Myfembree carries a boxed warning for blood clots and vascular events, including deep vein thrombosis, pulmonary embolism, stroke, and heart attack. Other serious concerns include loss of bone mineral density, depression and suicidal thoughts, liver injury, elevated blood pressure, gallbladder disease, and early pregnancy loss. Women older than 35 who smoke and those with uncontrolled hypertension have particularly significant vascular risks.
Myfembree treats heavy menstrual bleeding associated with uterine fibroids and moderate to severe endometriosis-related pain in premenopausal women.
Each tablet contains relugolix 40 mg, estradiol 1 mg, and norethindrone acetate 0.5 mg.
The recommended total treatment duration is limited to 24 months because bone loss can continue and might not fully reverse after discontinuation.
Yes. Its boxed warning concerns serious blood clots and vascular events, including stroke and heart attack.
Clinical Review - Relugolix-Estradiol?Norethindrone Acetate (Myfembree). Canada's Drug Agency. https://www.ncbi.nlm.nih.gov/books/NBK622146/. Date Accessed October 16, 2026.
DailyMed - MYFEMBREE (relugolix, estradiol, and norethindrone acetate) tablet. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=fc3feb73-cc84-43a8-aa32-b262460495e8. Date Accessed October 16, 2026.
MYFEMBREE (relugolix, estradiol, and norethindrone acetate) Prescribing Information. U.S. Food and Drug Administration. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/214846s007lbl.pdf. Date Accessed October 16, 2026.
Relugolix. PubChem. https://pubchem.ncbi.nlm.nih.gov/compound/Relugolix. Date Accessed October 16, 2026.
Relugolix, Estradiol, and Norethindrone. MedlinePlus. https://medlineplus.gov/druginfo/meds/a622069.html. Date Accessed October 16, 2026.